 |
85 Diseases |  |
38 Trials |
|
38 Trials |  |
1659 News |  |
| «12345678910111213...1314» |
- Humalog pen (insulin lispro) / Eli Lilly, Lyumjev (insulin lispro-aabc injection) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Indirect Treatment Comparison (ITC) of ULTRA-RAPID Lispro Insulin (URLI) Versus FAST-Acting Insulin Aspart (FASTER ASPART) in Patients with Type 1 Diabetes (T1DM) () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1852;
Key trials identified for URLi (PRONTO-T1D; URLi versus insulin lispro) and faster aspart (onset 1 and 8; faster aspart versus insulin aspart), with basal insulin, reported the endpoints (including primary endpoints) at 26 weeks...CONCLUSIONS : URLi demonstrated non-inferiority in lowering HbA1c at week 26 and superiority in reducing PPG excursions at 2, 3 and 4 hours versus faster aspart in adults with T1DM. Weight increase and severe hypoglycaemia did not differ significantly between URLi and faster aspart.
- | Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
Enrollment open, Phase classification: Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal (clinicaltrials.gov) - Sep 21, 2020
P3, N=72, Recruiting, Sponsor: Medical University of Warsaw
Weight increase and severe hypoglycaemia did not differ significantly between URLi and faster aspart. Not yet recruiting --> Recruiting | Phase classification: P4 --> P3
- || NovoLog (insulin aspart) / Novo Nordisk
Clinical, Journal: A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). (Pubmed Central) - Sep 8, 2020
Not yet recruiting --> Recruiting | Phase classification: P4 --> P3 FA provides an effective and safe option for CSII treatment in type 1 diabetes.
- || Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk, BioChaperone lispro (ultra fast-acting insulin analog) / Adocia
Clinical, Journal: BioChaperone Lispro (BCLIS) vs faster aspart (FIA) and insulin aspart (ASP) in patients with type 1 diabetes on continuous subcutaneous insulin infusion: a randomized euglycemic clamp study. (Pubmed Central) - Sep 8, 2020
BCLIS also demonstrated significantly higher early exposure (AUCins,0-60min) and lower late exposure (AUCins,120-600min) than both other insulins. In patients with type 1 diabetes using an insulin pump, BCLIS better mimics prandial insulin secretion and action than ASP and shows a faster off-PD than FIA.
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P4 trial: TRANSITION-T2D: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (clinicaltrials.gov) - Sep 3, 2020
P4, N=100, Not yet recruiting, Sponsor: The Cleveland Clinic
- || Clinical, Journal, Monotherapy: Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial. (Pubmed Central) - Aug 30, 2020
P4
Although there was no difference in change of GV between Exenatide and BIAsp30, exenatide provided more improvement in postprandial glucose excursion and weight control, without increasing the risk of hypoglycemia in Chinese patients with T2DM whose blood glucose was inadequately controlled with metformin. These findings may provide new options for patients who choose further hypoglycemic treatment, especially in patients with obesity who have large postprandial plasma glucose excursions.
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion date, Trial primary completion date: The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients (clinicaltrials.gov) - Aug 25, 2020
P2/3, N=80, Recruiting, Sponsor: University of Minnesota
These findings may provide new options for patients who choose further hypoglycemic treatment, especially in patients with obesity who have large postprandial plasma glucose excursions. Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2020 --> Jul 2021
- Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] United States Supreme Court provides key guidance for those participating in the biological drug approval “Patent Dance” when a second party seeks marketing license on an already approved biological drug product (On Demand Oral) - Aug 20, 2020 - Abstract #ACSFall2020ACS-Fall_3190;
The Court clarified what remedies are available to the first drug company (in this case Amgen) when the second drug company (here Sandoz) fails to fulfil one of its obligations when the Patent Dance is in play. The present talk will provide an overview of the BPCIA and the obligations of the dance partners, and discuss key pronouncements made the Supreme Court in its 2017 opinion.
- Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] United States Supreme Court provides key guidance for those participating in the biological drug approval “Patent Dance” when a second party seeks marketing license on an already approved biological drug product (Broadcast) - Aug 20, 2020 - Abstract #ACSFall2020ACS-Fall_239;
The Court clarified what remedies are available to the first drug company (in this case Amgen) when the second drug company (here Sandoz) fails to fulfil one of its obligations when the Patent Dance is in play. The present talk will provide an overview of the BPCIA and the obligations of the dance partners, and discuss key pronouncements made the Supreme Court in its 2017 opinion.
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: MIRE: Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes (clinicaltrials.gov) - Aug 19, 2020
P4, N=40, Recruiting, Sponsor: University Hospital, Strasbourg, France
The present talk will provide an overview of the BPCIA and the obligations of the dance partners, and discuss key pronouncements made the Supreme Court in its 2017 opinion. Not yet recruiting --> Recruiting | Trial completion date: May 2023 --> Aug 2023 | Initiation date: May 2020 --> Aug 2020 | Trial primary completion date: May 2023 --> Aug 2023
- | NovoLog (insulin aspart) / Novo Nordisk
Was she also in disbelief the first time she tried to buy her Novolog at the pharmacy and saw it was $300 per vial? (Twitter) - Aug 10, 2020
- | Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial completion date, Trial primary completion date, Metastases: Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) (clinicaltrials.gov) - Aug 9, 2020
P=N/A, N=75, Active, not recruiting, Sponsor: Imperial College London
Not yet recruiting --> Recruiting | Trial completion date: May 2023 --> Aug 2023 | Initiation date: May 2020 --> Aug 2020 | Trial primary completion date: May 2023 --> Aug 2023 Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- |||| Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
Trial completion: SWITCH: Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (clinicaltrials.gov) - Aug 8, 2020
P4, N=384, Completed, Sponsor: Sanofi
Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021 Active, not recruiting --> Completed
- | NovoLog (insulin aspart) / Novo Nordisk
Preclinical, Journal: Insulin-Loaded Barium Salt Particles Facilitate Oral Delivery of Insulin in Diabetic Rats. (Pubmed Central) - Aug 6, 2020
Therefore, oral formulations of insulin/BaSO and insulin/BaCO particles were observed as effective as native insulin aspart subcutaneous formulation in terms of onset and duration of action. Further investigation will be needed to reveal bioavailability and mechanism of action of this novel Nano-Insulin formulations.
- | NovoLog (insulin aspart) / Novo Nordisk
Journal: A survey of physician experience and treatment satisfaction using fast-acting insulin aspart in people with type 1 or type 2 diabetes. (Pubmed Central) - Aug 4, 2020
Further investigation will be needed to reveal bioavailability and mechanism of action of this novel Nano-Insulin formulations. Reported physician and patient experiences of using faster aspart have been positive, and better PPG control and increased dosing flexibility are expected to improve glycemic management.
- ||||||| GP40071 (insulin aspart biosimilar) / Geropharm
Trial completion, Trial completion date: Efficacy and Safety of GP40071 Compared to NovoRapid (clinicaltrials.gov) - Jul 22, 2020
P3, N=264, Completed, Sponsor: Geropharm
Reported physician and patient experiences of using faster aspart have been positive, and better PPG control and increased dosing flexibility are expected to improve glycemic management. Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Jan 2020
- || Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
My worry with closed loop systems is that there is a 15 min delay between BG and CGM reading then ~30 min until Humalog/Novolog peaks. That's a lot of time for my pancakes and syrup to kill me first. (Twitter) - Jul 16, 2020
- | NovoLog (insulin aspart) / Novo Nordisk
Clinical, Journal: Fast-acting insulin aspart in subjects with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart. (Pubmed Central) - Jul 16, 2020
P1
In subjects with T2D, faster aspart was associated with earlier onset and greater initial exposure and glucose-lowering effect compared with IAsp, as previously shown in subjects with type 1 diabetes. ClinicalTrials.
- || NovoLog (insulin aspart) / Novo Nordisk
Clinical, Review, Journal: Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. (Pubmed Central) - Jul 16, 2020
Experience from clinical practice indicates that all pump settings should be reviewed when starting faster aspart in CSII, and that the use of continuous glucose monitoring or flash glucose monitoring, along with a good understanding of meal content and bolus type, may also facilitate optimal use. This review summarizes the available clinical evidence for faster aspart administered via CSII and highlights practical considerations based on clinical experience that may help healthcare providers and people with T1D successfully initiate and adjust faster aspart in CSII.
- ||||||| SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi, Lantus (insulin glargine) / Sanofi
Trial completion: GEMELLI X: Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (clinicaltrials.gov) - Jul 16, 2020
P3, N=210, Completed, Sponsor: Sanofi
This review summarizes the available clinical evidence for faster aspart administered via CSII and highlights practical considerations based on clinical experience that may help healthcare providers and people with T1D successfully initiate and adjust faster aspart in CSII. Active, not recruiting --> Completed
- ||||| NovoLog (insulin aspart) / Novo Nordisk
European regulatory: Die Europäische Arzneimittelagentur (#EMA) hat Insulin aspart #Sanofi zur Behandlung von Typ-1- oder Typ-2-#Diabetes zugelassen. @EMA_News #Insulinaspart #Insulin #Pharmazie https://t.co/tk9oUdOanC (Twitter) - Jul 15, 2020
- || NovoLog (insulin aspart) / Novo Nordisk
Une pompe j’dis pas, surtout en HCLs, un stylo de novorapid, bof. (Twitter) - Jul 12, 2020
- | metformin / Generic mfg., NovoLog (insulin aspart) / Novo Nordisk
Journal: Baseline nocturnal glucose change: a predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes. (Pubmed Central) - Jul 11, 2020
For baseline HbA1c, significantly greater treatment differences were observed for change in end-of-trial PPG increments, but not end-of-trial HbA1c. In conclusion, both nocturnal glucose change and PPG increments may be more useful than HbA1c for identifying subgroups of people with T2D that would most benefit from bolus intensification.
- | NovoLog (insulin aspart) / Novo Nordisk
Review, Journal: Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus. (Pubmed Central) - Jul 9, 2020
However, additional studies should be completed to determine the role of faster insulin aspart in pregnant and pediatric patients, along with patients prescribed insulin pumps. This article evaluates and summarizes the pharmacokinetics and pharmacodynamics of faster insulin aspart for patients with type 1 or 2 diabetes mellitus, and summarizes its application to clinical practice.
- || NovoLog (insulin aspart) / Novo Nordisk
Clinical, Journal: Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus. (Pubmed Central) - Jul 9, 2020
P1, P3
Higher anti-IAsp antibodies increase total IAsp concentrations but do not influence faster aspart nor IAsp pharmacodynamics. CLINICALTRIALS.
- |||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P3 trial: Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jul 6, 2020
P3, N=160, Not yet recruiting, Sponsor: Boston Medical Center
- ultra-rapid acting insulin (AT247) / Arecor, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart and fast insulin aspart (Salzburg Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_608;
AT247 has a superior (left-shifted) time-action and time-concentration profile as compared to both IAsp and fast IAsp. Clinical Trial Registration Number EudraCT: 2018-003934-34
- NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Postprandial glucose control using the Medtronic Advanced Hybrid Closed Loop System: faster-acting insulin aspart vs insulin aspart (Poster Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_488;
FiAsp appears to confer an advantage compared with Asp for PPG control whilst using AHCL even in subjects with high overall TIR. Clinical Trial Registration Number ACTRN12619000469112
- NovoLog (insulin aspart) / Novo Nordisk, Afrezza (recombinant human insulin inhalation) / MannKind
[VIRTUAL] Technosphere insulin use in type 1 and type 2 diabetes is associated with weight loss compared to insulin analogues or insulin mixtures over 26 Weeks (Poster Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_481;
P3
These changes appear to be independent of changes in A1C. In contrast to the weight gain generally observed with addition of SC mealtime insulin, addition of TI appears to be associated with a weight advantageous clinical profile.
- Tresiba (insulin degludec) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Type 1 diabetes: analysis of real-world insulin injection patterns (Poster Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_300;
These real-world data provide a unique insight into the everyday bolus and basal adherence of paediatric and adult patients with T1D. Furthermore, the results illustrate the flexibility needed for basal injections to enable optimal management of T1D.
- NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Investigating the safety and glycaemic control of fast-acting insulin aspart with a closed-loop delivery system in adults with type 1 diabetes (Poster Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_198;
P2
Improvements in glycaemic control at non-default t max settings were observed. Clinical Trial Registration Number NCT03816761
- NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] The burden of mealtime insulin dosing in adults and children with type 1 diabetes (Poster Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_126;
Based on the study findings, although the importance of accurate mealtime dosing was well recognised, bolus insulin dosing still poses clear challenges to most people with T1D. Given the choice, the majority of participants would prefer to administer insulin immediately prior to or following a meal, as this was perceived to improve quality of life.
- Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Efficacy and safety of fast-acting insulin aspart in adults with type 2 diabetes with different insulin requirements (Poster Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_86;
P3
Treatment difference (FA vs IAsp) in change from baseline in PPG increments was unaffected by bolus insulin dose; however hypoglycaemia risk may be lower with FA vs IAsp in adults with long-standing type 2 diabetes and high bolus insulin requirements. Clinical Trial Registration Number NCT03268005
- NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Long duration diabetes is associated with a lower C-peptide concentration and response to aerobic exercise in individuals with type 1 diabetes (Poster Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_23;
These data reveal new insights into the impact of acute exercise as a physiological stimulus on pancreatic β-cell function in people with T1D. Clinical Trial Registration Number DRKS00013509
- NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Endogenous Insulin and C-Peptide Suppression Test Using a Rapid-Acting Insulin Analog in the Diagnosis of Insulinoma () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1036;
This study aimed to examine efficacy of modified CPS, so-called insulin and C-peptide suppression test (ICPS) by using an RA (insulin aspart) in the diagnosis of insulinoma...There was a high correlation of 89% between using PCP and PI responses. In conclusion, ICPS using an RA is effective in the diagnosis of insulinoma.
- NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Faster Acting Insulin Aspart in Patients With Gestational Diabetes Mellitus - an Early Experience From India () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_955;
Mean number of FiASP injections per day was 2.88 ± 0.39. Faster acting insulin aspart was found safe in pregnancy, however, more studies with double-blind, standard controlled studies are required to confirm the findings of this study.
- Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] A Test for Variation in Insulin Concentrations at the Wilford Hall Ambulatory and Surgical Center () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_932;
If this is not met, investigation of the cold supply chain should identify the source of the problem and address it. Our study demonstrates that Novolog and Lantus were meeting the minimum concentration upon receipt at the pharmacy.
- Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] Unusual Presentation of Diabetic Ketoacidosis Associated with Hypernatremia in Adult Patient () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_913;
When there is marked osmotic diuresis, DKA may present with a normal or even elevated serum Na concentration, despite a markedly elevated serum BG. To best of our knowledge, this is the second case to report an unusual DKA presenting with hypernatremia in adult patient.
- Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
[VIRTUAL] An Unusual and Enigmatic Etiology for Diabetic Ketoacidosis: Safety Needles () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_903;
Canadian Medical Journal Journal. 2012 Mar 20;184(5):557–558.
- | Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
It is free if you are Canadian but last time I checked it was about $32.00 for Humalog and Novolog compared to $300.00 in the US (Twitter) - Jun 19, 2020
- | NovoLog (insulin aspart) / Novo Nordisk
Journal: Biosimilars and Novel Insulins. (Pubmed Central) - Jun 9, 2020
Faster aspart is the first ultrafast-acting insulin. New upcoming clinical trials and more clinical experience with faster aspart will show the real potential of this new insulin.
- || Enrollment closed, Trial completion date, Trial primary completion date: HbA1c Variability in Type II Diabetes (clinicaltrials.gov) - Jun 9, 2020
P=N/A, N=150, Active, not recruiting, Sponsor: Weill Cornell Medical College in Qatar
New upcoming clinical trials and more clinical experience with faster aspart will show the real potential of this new insulin. Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Sep 2020 | Trial primary completion date: Apr 2019 --> Jun 2020
- |||| NovoLog (insulin aspart) / Novo Nordisk
Clinical: How would patients know that the same insulin aspart that your doctor prescribed, can be bought at quarter of the price if the prescription was for the generic? @goodrx (Twitter) - Jun 7, 2020
- |||| NovoLog (insulin aspart) / Novo Nordisk
Clinical: How would patients know that the same insulin aspart that your doctor prescribed, can be bought at quarter of the price if the prescription was for the generic? (Twitter) - Jun 7, 2020
- | Byetta (exenatide) / AstraZeneca
Trial completion, Enrollment change: New Onset Type 1 Diabetes: Role of Exenatide (clinicaltrials.gov) - Jun 4, 2020
P4, N=14, Completed, Sponsor: Albert Einstein College of Medicine
Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Sep 2020 | Trial primary completion date: Apr 2019 --> Jun 2020 Recruiting --> Completed | N=20 --> 14
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P4 trial: PLATEAU: The Efficacy and Safety of Faster Insulin Aspart (Fiasp (clinicaltrials.gov) - Jun 3, 2020
P4, N=45, Recruiting, Sponsor: Mountain Diabetes and Endocrine Center
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
New P4 trial: Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - Jun 3, 2020
P4, N=260, Recruiting, Sponsor: Emory University
- | metformin / Generic mfg., Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, NovoLog (insulin aspart) / Novo Nordisk
Journal: Myopathy secondary to empagliflozin therapy in type 2 diabetes. (Pubmed Central) - Jun 3, 2020
They are now recommended as second-line pharmacotherapy (in conjunction with metformin) in patients with type 2 diabetes and established atherosclerotic heart disease, heart failure or chronic kidney disease due to their favourable effects on cardiovascular and renal outcomes...A high degree of suspicion is required to diagnose drug-induced myopathy, with a temporal relationship between starting the medication and symptom onset being the main indicator. Recognition of drug-induced myopathy is essential, as discontinuation of the offending drug typically improves symptoms.
- | Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
Trial initiation date: Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal (clinicaltrials.gov) - May 28, 2020
P4, N=70, Not yet recruiting, Sponsor: Medical University of Warsaw
Recognition of drug-induced myopathy is essential, as discontinuation of the offending drug typically improves symptoms. Initiation date: Jul 2019 --> Jun 2020